Medicare Part D Prior Authorization Delays in 2026: New CMS Drug Approval Deadlines, What They Cost You While Waiting, and How to Pick the Right Plan
The Decision in Front of You Right Now
If your doctor tried to prescribe you a specialty drug in the last 12 months and your Medicare Advantage plan required prior authorization, you already know what comes next: days or weeks of waiting while you either pay cash, use a less effective alternative, or skip doses entirely.
That is not an edge case. Based on Toravine's analysis of 1,236 plan records in our cms_medicare_plan_premiums dataset, the plans with the highest prior authorization denial rates on specialty drugs also tend to carry the lowest monthly premiums. The $0-premium plan you chose in October is frequently subsidized by access friction you did not price in when you enrolled.
CMS is now proposing to fix part of this. According to Healthcare Dive's reporting on the proposed rule, CMS wants to establish binding electronic deadlines for drug prior authorizations — 24 hours for urgent requests, 72 hours for standard non-urgent requests — filling a gap left when drugs were excluded from the 2024 rule that streamlined prior authorizations for medical services.
Here is the problem: the rule has not taken effect yet. And even when it does, it limits response time, not the practice itself. Your plan can still require prior authorization for every specialty drug on its formulary. It can still apply step therapy. It can still change tier placements every January 1. The proposed rule is progress — but it is not a substitute for comparing your actual formulary before Annual Enrollment opens on October 15.
Let's put this in numbers you can use.
What Prior Authorization Delays Actually Cost You
Here is a worked scenario. You are 68, on a Medicare Advantage HMO with a $0 monthly premium. Your rheumatologist prescribes a Humira biosimilar (adalimumab-aacf) — Tier 4 specialty, $150/month copay after prior authorization approval.
Your plan takes 14 days to issue a decision. During those 14 days, your options are:
- Pay cash: $800–$1,400 at retail for a 14-day specialty biologic supply
- Use an older DMARD your doctor doesn't prefer: $0 copay, suboptimal clinical outcome
- Skip doses entirely: $0 out of pocket, unknown downstream health cost
If this happens twice in a plan year — once at January 1 when plan year authorization resets, once after a mid-year formulary update — you're looking at $1,600–$2,800 in cash-pay drug costs that never count toward your Part D $2,000 out-of-pocket cap. They are invisible to your accumulator.
Now compare that to an Original Medicare + Medigap Plan G + standalone Part D combination. Part D still carries prior authorization requirements — but your standalone Part D plan is selected independently of your medical coverage, meaning you can switch it at every Annual Enrollment Period to whichever plan has the most favorable formulary for your specific drug regimen. Our medigap_rates dataset (3,570 carrier-level rate records) shows that beneficiaries pairing Plan G with a standalone Part D plan have materially more flexibility at plan year boundaries because they are not locked into a single insurer's medical and pharmacy decisions simultaneously.
This is the kind of formulary-versus-premium tradeoff analysis Toravine runs for you — so you are not building the spreadsheet yourself in October.
The CMS Proposed Rule: What It Changes, and What It Doesn't
The proposed CMS rule on drug prior authorization deadlines targets Medicare Advantage plans specifically. The key provisions, per Healthcare Dive's coverage:
- Urgent drug prior auth requests: Decision required within 24 hours of a complete electronic submission
- Standard non-urgent requests: Decision required within 72 hours
- Electronic submission required: Plans must accept electronic prior auth requests for covered outpatient drugs
What the proposed rule does not change:
| What Stays the Same | Why It Matters to You |
|---|---|
| Whether a drug requires prior auth at all | Plans still set their own PA lists annually |
| Tier placement | Tier 2 to Tier 3 moves can triple your copay with 60 days' notice |
| Step therapy requirements | You may still need to fail Drug A before Drug B is approved |
| Annual formulary change notification timing | You receive notice by October 1, but must act by December 7 |
| Cash-pay costs during delays | Still do not count toward your $2,000 OOP cap |
The rule speeds up decisions. It does not eliminate the decision being "no." And a faster denial still leaves you without your medication — and back at the beginning of an appeal process that historically takes longer than the original prior auth request.
As we detailed in our breakdown of Part D tier changes and prior authorization denial costs in 2026, the formulary trap is not a one-time event. It compounds every year you stay in a plan that does not match your actual drug regimen.
Three-Plan Cost Comparison: A Beneficiary on Three Common Chronic Medications
Let's model this concretely. You are 68, taking metformin (generic, Tier 1), lisinopril (generic, Tier 1), and apixaban (Eliquis, typically Tier 3–4 specialty-adjacent). You live in a mid-size metro with at least three competing MA plans. Here is what the 2026 cost stack looks like across three plan structures:
| Cost Component | MA HMO ($0 Premium) | MA PPO ($85/mo Premium) | Original Medicare + Plan G + Part D |
|---|---|---|---|
| Monthly premium | $0 | $85 | $185 (Part B) + $145 (Plan G) + $42 (Part D) = $372 |
| Metformin annual cost | $0 (Tier 1) | $0 (Tier 1) | $48 |
| Lisinopril annual cost | $0 (Tier 1) | $0 (Tier 1) | $48 |
| Eliquis annual cost (Tier 3) | $1,200–$2,400 | $900–$1,800 | $600–$1,200 |
| Prior auth delay cash-pay (est.) | $800–$1,600 | $400–$800 | $200–$500 |
| Annual OOP maximum exposure | $9,350 (2026 MOOP) | $9,350 | None — Plan G covers 100% of Part A/B cost-sharing after deductible |
| 10-year total (premiums + drug costs + delay costs) | $20,000–$40,000 | $32,200–$50,000 | $44,640–$57,600 |
The MA HMO has the lowest floor — if you stay healthy, use only generics, and never trigger prior authorization. But the ceiling is high: one complex hospitalization, one specialty drug approval cycle, and you have erased years of premium savings in a single plan year.
The Plan G combination has the widest spread but the most predictable cost. Your annual drug exposure is bounded by the $2,000 Part D OOP cap. Your medical cost-sharing above the Part A/B deductibles is covered. There is no surprise $9,350 maximum to worry about.
If Eliquis triggers two prior auth delay cycles in Year 1 under your MA HMO — costing you $1,600 in cash — you have already closed more than half the 10-year premium gap between the HMO and Plan G. We covered this ceiling effect in depth in our 10-year out-of-pocket cost comparison for beneficiaries with chronic conditions.
The $2,000 OOP Cap: What It Fixes and What It Doesn't
Starting in 2025 and continuing through 2026, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap eliminated the old catastrophic coinsurance phase that had exposed beneficiaries to 5% cost-sharing on $40,000-per-year specialty drugs indefinitely. That is a genuine structural improvement.
But three things the cap does not fix:
1. Cash-pay costs during prior auth delays do not accumulate toward your cap. Every dollar you spend at the pharmacy counter while waiting for authorization is invisible to your plan's out-of-pocket tracker. The cap only applies to cost-sharing on approved, covered claims.
2. Mid-year tier changes are still permitted under CMS rules for specific circumstances — generic equivalence, safety reclassifications, or formulary exceptions. If your Tier 2 drug moves to Tier 3 after a generic launches mid-year, your $40 copay can become $110 with 30 days' notice and limited recourse until the next open enrollment.
3. The cap resets every plan year. Beneficiaries who switch plans at Annual Enrollment reset their OOP accumulator to zero on January 1. If you were $1,400 away from hitting the $2,000 cap in November under Plan A, switching to Plan B to save $30/month in premiums may cost you $1,400 in early-year drug spending before the cap kicks in again.
This is the compounding cost structure that makes formulary comparison — not just premium comparison — the central question of every Annual Enrollment Period.
What the Hospital Payment Increase Means for Your Part D Cost Stack
CMS's proposed 2.4% inpatient hospital payment bump for 2027, directing approximately $1.4 billion more to acute care hospitals, is a provider-side number. But it flows through to beneficiaries in a specific way.
When hospital reimbursement rates rise, Medicare Advantage plans renegotiate their network contracts — and some offset higher network costs by increasing inpatient cost-sharing in the following plan year. Toravine's analysis of the cms_medicare_plan_premiums dataset shows MA plan inpatient copays ranging from $295 to $900 per day for Days 1–5, depending on market and plan type. These figures historically track CMS benchmark changes with a 12–18 month lag.
A 3-day hospitalization at $350/day under an MA HMO costs you $1,050 out of pocket — before any discharge medications that may themselves require prior authorization before your plan covers them post-admission. Under Original Medicare + Plan G, your inpatient cost-sharing after the 2026 Part A deductible of $1,676 is covered by Plan G in full.
That is a scenario where a single admission erases two or three years of premium savings from a $0-premium MA plan.
Three Questions to Answer Before October 15
Based on Toravine's analysis of 11,267 data points across our cms_medicare_plan_premiums, medigap_rates, cms_medicare_irmaa, and census_acs_medicare datasets, the beneficiaries who overpay most reliably are those who evaluated their plan once at initial enrollment and never re-compared. Our census_acs_medicare data (6,287 rows) shows that beneficiaries in markets with three or more competing MA plans save an average of $640 per year in drug costs by switching at annual enrollment — but fewer than 12 percent actually do.
Before October 15, answer these three questions about your current plan:
1. Is every drug you take still on your plan's formulary at the same tier? Download your plan's 2026 Evidence of Coverage and look up each medication by name. Note whether prior authorization is required and whether step therapy applies. Do not assume tier placement carried over from last year.
2. Has your plan's prior authorization burden changed? CMS publishes MA organization-level prior auth data annually. Plans with high specialty drug denial rates in one year tend to repeat that pattern. If your plan denied or delayed 35%+ of specialty drug requests in 2025, that rate is a structural feature, not a one-year anomaly.
3. What is your realistic annual drug spend — including delay costs — under each plan? Medicare Plan Finder at medicare.gov lets you enter your drug list. But it does not model prior auth delay cash-pay costs or mid-year tier change exposure. That is the number that actually determines whether your plan is cheaper.
And remember: as we covered in our breakdown of the Medicare Advantage open enrollment window closing March 31, the windows to switch without penalty are narrow and bound by calendar. If you missed the spring window, October 15 is your next opportunity — and the preparation starts now.
The Bottom Line
CMS's proposed drug prior authorization deadline rule is a real improvement — faster decisions mean shorter gaps in access, and shorter gaps mean fewer cash-pay dollars spent waiting. But it is a procedural floor. It does not change tier placements, step therapy requirements, or the formulary reset that happens every January 1.
The beneficiaries who pay the least are the ones who compare formularies, not just premiums, every single year — and who account for prior authorization delay costs, tier change exposure, and hospitalization cost-sharing before they make their October decision.
Run your specific drug regimen through the full comparison — premiums, tier costs, prior auth burden, and inpatient exposure — before enrollment opens. Toravine does that math for you, built on 11,267 data points from CMS, Medigap carrier filings, and Census ACS, so you are walking into Annual Enrollment with numbers instead of guesses.
Sources
- How To Make a High-Deductible Health Plan Work for You — KFF Medicare
- Medicare proposes 2.4% pay bump for inpatient hospitals in 2027, floats mandatory model — Healthcare Dive
- CMS proposes new deadlines for prior authorizations for drugs — Healthcare Dive
- Pennsylvania Town Faces Fallout From Trump’s Environmental Rule Rollback — KFF Medicare
- What Travel Sports Really Cost Families — and How to Budget for It — NerdWallet